![](https://news.europawire.eu/wp-content/uploads/2024/05/Boehringer-Ingelheim-and-OSE-Immunotherapeutics-Forge-New-Paths-in-Disease-Treatment-Collaboration-144x144.jpg)
(IN BRIEF) Boehringer Ingelheim and OSE Immunotherapeutics announce a significant expansion of their partnership, introducing two novel projects to develop pioneering treatments alongside their ongoing anti-SIRPα immuno-oncology initiatives. The expansion includes broadening therapeutic evaluations to encompass cardiovascular-renal-metabolic (CRM) diseases and … Read the full press release